

# Giuseppe Vergaro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5777663/publications.pdf>

Version: 2024-02-01

121  
papers

3,189  
citations

172386

29  
h-index

189801

50  
g-index

135  
all docs

135  
docs citations

135  
times ranked

3735  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
2	Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 909-920.	2.3	136
3	Biomarkers for the diagnosis and management of heart failure. <i>Heart Failure Reviews</i> , 2022, 27, 625-643.	1.7	135
4	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 280-286.	1.9	127
5	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	1.2	126
6	Treatment of cardiac transthyretin amyloidosis: an update. <i>European Heart Journal</i> , 2019, 40, 3699-3706.	1.0	121
7	Clinical and Prognostic Significance of sST2 in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2193-2203.	1.2	110
8	Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	1.9	104
9	Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. <i>Hypertension</i> , 2016, 67, 606-612.	1.3	90
10	Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1795-1807.	1.2	71
11	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. <i>Clinica Chimica Acta</i> , 2015, 443, 29-38.	0.5	70
12	CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. <i>Europace</i> , 2014, 16, 71-80.	0.7	64
13	Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 497-504.	1.4	64
14	RNA-targeting and gene editing therapies for transthyretin amyloidosis. <i>Nature Reviews Cardiology</i> , 2022, 19, 655-667.	6.1	64
15	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013441.	1.6	62
16	Prognostic Value of Plasma Renin Activity in Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 246-251.	0.7	61
17	Prognostic significance of myocardial extracellular volume fraction in nonischemic dilated cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 681.	0.6	61
18	Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2015, 184, 96-100.	0.8	60

#	ARTICLE	IF	CITATIONS
19	Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2019, 296, 91-97.	0.8	60
20	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1806-1815.	0.8	60
21	Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. <i>European Journal of Heart Failure</i> , 2022, 24, 2342-2351.	2.9	51
22	Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. <i>Journal of Internal Medicine</i> , 2015, 277, 605-614.	2.7	44
23	Sex-related differences in chronic heart failure. <i>International Journal of Cardiology</i> , 2018, 255, 145-151.	0.8	41
24	The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?. <i>International Journal of Cardiology</i> , 2018, 267, 188-192.	0.8	40
25	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 12-18.	1.4	38
26	Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1288-1303.	1.2	35
27	Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. <i>European Journal of Internal Medicine</i> , 2020, 80, 66-72.	1.0	34
28	Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. <i>Journal of the American Heart Association</i> , 2021, 10, e020358.	1.6	34
29	Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 84.	1.6	33
30	Use of biomarkers to diagnose and manage cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2021, 23, 217-230.	2.9	33
31	Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 64-74.	0.7	32
32	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	0.8	32
33	Therapies for cardiac light chain amyloidosis: An update. <i>International Journal of Cardiology</i> , 2018, 271, 152-160.	0.8	31
34	Upright Cheyne-Stokes Respiration in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2934-2946.	1.2	31
35	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 735-742.	1.9	30
36	Contribution of the Lung to the Genesis of Cheyne-Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time. <i>Journal of the American Heart Association</i> , 2019, 8, e012419.	1.6	28

#	ARTICLE	IF	CITATIONS
37	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	0.8	28
38	Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. <i>International Journal of Cardiology</i> , 2013, 167, 711-715.	0.8	27
39	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2018, 271, 324-330.	0.8	27
40	Targeting Inflammation With Nanosized Drug Delivery Platforms in Cardiovascular Diseases: Immune Cell Modulation in Atherosclerosis. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 177.	2.0	26
41	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	2.9	26
42	Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2021, 23, 231-239.	2.9	26
43	Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 125.	1.1	25
44	Clinical relevance of non-cardiac determinants of natriuretic peptide levels. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1515-23.	1.4	24
45	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. <i>International Journal of Cardiology</i> , 2019, 293, 137-142.	0.8	24
46	A simple echocardiographic score to rule out cardiac amyloidosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13449.	1.7	24
47	Percutaneous Treatment of Iatrogenic Pseudoaneurysms by Cyanoacrylate-Based Wall-Gluing. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 669-675.	0.9	22
48	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. <i>Clinica Chimica Acta</i> , 2015, 443, 85-93.	0.5	22
49	Current and emerging drug targets in heart failure treatment. <i>Heart Failure Reviews</i> , 2022, 27, 1119-1136.	1.7	22
50	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	2.9	22
51	Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure. <i>International Journal of Cardiology</i> , 2019, 289, 76-82.	0.8	21
52	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization—the first insight from the AC-TIVE Study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e173-e177.	0.8	21
53	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	1.5	20
54	Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 24, 130-141.	0.5	18

#	ARTICLE	IF	CITATIONS
55	Deep-learning-based cardiac amyloidosis classification from early acquired pet images. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2327-2335.	0.7	16
56	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13598.	1.7	16
57	Molecular Autopsy of Sudden Cardiac Death in the Genomics Era. <i>Diagnostics</i> , 2021, 11, 1378.	1.3	16
58	Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches. <i>Current Pharmaceutical Design</i> , 2016, 22, 4807-4822.	0.9	16
59	Concordant Versus Discordant Left Bundle Branch Block in Heart Failure Patients: Novel Clinical Value of an Old Electrocardiographic Diagnosis. <i>Journal of Cardiac Failure</i> , 2010, 16, 320-326.	0.7	15
60	High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2022, 98, 61-68.	1.0	15
61	Sacubitrilâ€“valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021, 330, 112-119.	0.8	14
62	Mineralocorticoid receptor antagonists for heart failure: a realâ€“life observational study. <i>ESC Heart Failure</i> , 2018, 5, 267-274.	1.4	13
63	Creatine deficiency and heart failure. <i>Heart Failure Reviews</i> , 2022, 27, 1605-1616.	1.7	13
64	Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 416-422.	0.6	12
65	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 889-895.	0.8	12
66	Management of complications of cardiac amyloidosis: 10 questions and answers. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1000-1005.	0.8	12
67	PET-CT evaluation of amyloid systemic involvement with [18F]-florbetaben in patient with proved cardiac amyloidosis: a case report. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 2025-2029.	1.4	11
68	Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1419-1430.	0.8	11
69	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2018, 273, 136-140.	0.8	11
70	Prognostic value of reverse remodelling criteria in heart failure with reduced or midâ€“range ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3014-3025.	1.4	11
71	Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity. <i>International Journal of Cardiology</i> , 2021, 333, 45-50.	0.8	11
72	Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 237-243.	1.4	10

#	ARTICLE	IF	CITATIONS
73	Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. <i>International Journal of Cardiology</i> , 2020, 307, 187-192.	0.8	9
74	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 530-545.	2.7	9
75	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2021, , 1.	1.7	9
76	Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 252-258.	1.4	9
77	Markers of Arrhythmogenic Risk in Hypertensive Subjects. <i>Current Pharmaceutical Design</i> , 2011, 17, 3062-3073.	0.9	8
78	Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 79-108.	0.9	7
79	Self-Inserted Needles in the Heart. <i>American Journal of Cardiology</i> , 2015, 116, 1315-1317.	0.7	6
80	Wet is bad: Residual congestion predicts worse prognosis in acute heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 201-202.	0.8	6
81	Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters. <i>International Journal of Cardiology</i> , 2018, 267, 141-142.	0.8	6
82	Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. <i>International Journal of Cardiology</i> , 2021, 336, 98-104.	0.8	6
83	Restrictive spirometry pattern and abnormal cardiopulmonary response to exercise in transthyretin cardiac amyloidosis. <i>European Respiratory Journal</i> , 2022, 59, 2102838.	3.1	6
84	Cardiac angiotensin receptor expression in hypothyroidism: back to fetal gene programme?. <i>Journal of Physiology</i> , 2008, 586, 7-8.	1.3	5
85	No Aldosterone Breakthrough With the Nephilysin Inhibitor Sacubitril. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3037-3038.	1.2	5
86	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 348.	1.0	5
87	How to take arms against central apneas in heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 743-755.	0.6	4
88	Cardiac light-chain deposition disease relapsing in the transplanted heart. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 135-137.	1.4	4
89	Clinical benefits of natriuretic peptides and galectin-3 are maintained in old dyspnoeic patients. <i>Archives of Gerontology and Geriatrics</i> , 2017, 68, 33-38.	1.4	4
90	Correction of procedural arterial pseudoaneurysms: established and novel procedures. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 843-850.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Is there a renal paradox in chronic heart failure?. International Journal of Cardiology, 2018, 267, 139-140.	0.8	3
92	Longer sleep duration and poor sleep quality as risk factors for hyperlipidaemia. European Journal of Preventive Cardiology, 2019, 26, 1285-1287.	0.8	3
93	Biomarkers for growth prediction of abdominal aortic aneurysm: A step forward(?). European Journal of Preventive Cardiology, 2020, 27, 130-131.	0.8	3
94	Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis. JACC: Case Reports, 2020, 2, 1182-1185.	0.3	3
95	Wild type transthyretin amyloidosis: Don't miss diagnosis!. International Journal of Cardiology, 2020, 312, 96-97.	0.8	3
96	Safety and efficacy of levosimendan in patients with cardiac amyloidosis. European Journal of Internal Medicine, 2020, 80, 114-116.	1.0	3
97	Î±-1 Antitrypsin as a potential biomarker in chronic heart failure. Journal of Cardiovascular Medicine, 2020, 21, 209-215.	0.6	3
98	Renin profiling predicts neurohormonal response to sacubitril/valsartan. ESC Heart Failure, 2021, 8, 719-724.	1.4	3
99	Natriuretic peptides. D'où venons-nous? Où allons-nous?. International Journal of Cardiology, 2018, 254, 256-257.	0.8	2
100	The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians. ESC Heart Failure, 2020, 7, 873-877.	1.4	2
101	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. JACC: Case Reports, 2021, 3, 450-454.	0.3	2
102	Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure. Heart, 2021, 107, 989-995.	1.2	2
103	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. Journal of Cardiovascular Translational Research, 2022, , 1.	1.1	2
104	The revolution of ATTR amyloidosis in cardiology: certainties, gray zones and perspectives. Minerva Cardiology and Angiology, 2022, 70, 248-257.	0.4	2
105	The search for efficient diagnostic and prognostic biomarkers of heart failure. Future Cardiology, 2016, 12, 327-337.	0.5	1
106	Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly. European Journal of Heart Failure, 2017, 19, 549-551.	2.9	1
107	Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry. International Journal of Cardiology, 2017, 248, 278-279.	0.8	1
108	Heart, kidney and FGF23: Les liaisons dangereuses. International Journal of Cardiology, 2018, 253, 120-121.	0.8	1

#	ARTICLE	IF	CITATIONS
109	The ST2-SCD score and the conundrum of sudden death prediction in heart failure. International Journal of Cardiology, 2019, 294, 50-51.	0.8	1
110	Left ventricular ejection fraction and coronary artery disease in the era of precision medicine. European Journal of Preventive Cardiology, 2019, 26, 1271-1272.	0.8	1
111	Integrated Imaging to Investigate Low-Flow Alarms of Left Ventricular Assist Devices. JACC: Case Reports, 2020, 2, 1457-1460.	0.3	1
112	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 28-36.	0.6	1
113	PLASMA RENIN ACTIVITY AND ANGIOTENSINOGEN M235T POLYMORPHISM ARE DETERMINANTS OF ALDOSTERONE ESCAPE IN PATIENTS WITH SYSTOLIC HEART FAILURE. Journal of the American College of Cardiology, 2011, 57, E260.	1.2	0
114	Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators. International Journal of Cardiology, 2017, 236, 348-349.	0.8	0
115	A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets. International Journal of Cardiology, 2018, 258, 203-204.	0.8	0
116	High-Sensitivity Troponins and Prognosis in Heart Failure. JACC: Heart Failure, 2018, 6, 440-441.	1.9	0
117	Heart & kidney failure: Who's afraid of renin angiotensin system blockade?. International Journal of Cardiology, 2018, 266, 195-196.	0.8	0
118	Relative hypochromia in acute heart failure to predict outcome and guide treatment: Ready for prime time?. International Journal of Cardiology, 2019, 286, 111-112.	0.8	0
119	How a large registry can explain pathophysiology: The case of anemia in the heart failure syndromes. International Journal of Cardiology, 2020, 298, 72-73.	0.8	0
120	Scoring frailty in patients hospitalized for heart failure: Impact on prognosis (and decision making.) Tj ETQqO O O rgBT /Overlock 10 Tf 50	0.8	0
121	Targeting precipitants to prevent heart failure hospitalization. Does season matter?. International Journal of Cardiology, 2022, , .	0.8	0